New drug cocktail targets tough CLL
NCT ID NCT03328273
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests two oral drugs—acalabrutinib and ceralasertib—in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has stopped responding to other treatments. The main goal is to check safety and find the right dose. It is not yet known if the combination will shrink tumors or extend life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib and ceralasertib (two cancer drugs taken as pills)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat CLL.
What could go wrong
This is a very early, small trial (12 people) focused on safety, not proof of effectiveness. The combination may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Krakow, 30-510, Poland
-
Research Site
Lodz, 93-510, Poland
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Cardiff, CF14 4XW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Oxford, OX3 7LJ, United Kingdom
-
Research Site
Southampton, SO16 6YD, United Kingdom